Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (NASDAQ: DRIO) announced a partnership with a major Northeast supermarket chain to enhance employees' cardiometabolic health starting in Q1 2023. This contract marks Dario's achievement of 100 enterprise contracts, validating its strategic position in the digital therapeutics market. The suite focuses on managing diabetes, hypertension, and weight management via integrated solutions. The Company anticipates growth due to increasing demand for multi-condition solutions from enterprise customers.

DarioHealth Corp. (NASDAQ: DRIO) announced a study published in Frontiers in Physiology on Dec. 19, 2022, showcasing its musculoskeletal solution's effectiveness in alleviating back pain. The research analyzed data from 981 users over eight weeks, revealing a 50% average reduction in pain, with 60% of users reporting significant relief after four weeks. The device offers real-time biofeedback to improve posture, resulting in better pain management. Dario's commitment to changing health management behaviors through innovative technology is emphasized, showing potential for chronic pain treatment.

DarioHealth Corp. (Nasdaq: DRIO) announced participation in two upcoming investor conferences. The 13th Annual Craig-Hallum Alpha Select Conference will take place on November 17, 2022, in New York City, featuring investor one-on-one meetings. Additionally, the BTIG Digital Health Forum is scheduled for November 21, 2022, as a virtual event, where President Rick Anderson will discuss digital therapeutics at 11:55 a.m. EST. DarioHealth focuses on digital solutions for chronic condition management, delivering personalized care through analytics and coaching.

DarioHealth Corp. (Nasdaq: DRIO) reported third quarter 2022 revenues of $6.6 million, a 17.3% increase from the previous year, driven by strong B2B growth, which now constitutes 63.5% of total revenue. The net loss decreased by 30.3% to $15.6 million. Notably, the company signed 85 B2B contracts valued at over $61 million, with a goal of reaching 100 by year-end. Operating expenses fell by 29.8%, contributing to improved financial health and gross margins of approximately 70% in the B2B segment. A conference call will be held on November 15, 2022.

DarioHealth Corp. (NASDAQ: DRIO) will announce its financial results for Q3 2022 on November 14, 2022, after market close. A conference call and webcast detailing these results will take place on November 15, 2022, at 8:30 am ET. The call will feature executives including CEO Erez Raphael and CFO Zvi Ben-David. Interested participants can join by dialing 1-844-826-3035 (domestic) or 1-412-317-5195 (international) with Conference ID 10173311. The replay will be available until December 15, 2022.

DarioHealth Corp. (Nasdaq: DRIO) has secured its first government contract with a Midwestern city to provide digital therapeutic solutions addressing chronic conditions for several thousand city employees. The contract, set to commence in Q1 2023, aims to enhance employee health in diabetes, hypertension, weight management, and behavioral health. This partnership expands Dario's employer footprint, supporting the City’s employee health strategy while aiming for better health outcomes at lower costs.

DarioHealth Corp. (NASDAQ: DRIO) presented new research at the IASP 2022 World Congress on Pain, highlighting the effectiveness of its biofeedback posture trainer in reducing back pain. The study, involving nearly 1,000 participants, found a direct correlation between increased usage of the device and improved posture, leading to reduced pain levels. Dr. Yifat Hershcovitz emphasized the importance of user engagement in achieving positive outcomes. This research furthers Dario's commitment to understanding the mechanisms of clinical improvement in their digital therapeutic solutions.